RecruitingNot Applicable

Assessment of Transcranial Alternating Current Stimulation's Clinical Efficacy in Treating Cognitive Impairment of Idiopathic Inflammatory Demyelinating Diseases

China128 participantsStarted 2025-05-30

Plain-language summary

This study aims to explore the imaging and electrophysiological characteristics of idiopathic inflammatory demyelinating diseases (IIDDs), and their correlation with clinical manifestations. It also evaluates the effectiveness of transcranial electrical stimulation in alleviating clinical symptoms of IIDDs patients, and analyzes the key factors affecting the treatment efficacy. By uncovering the overall and individual characteristics of IIDDs, this study seeks to enhance therapeutic outcomes through personalized neuromodulation programs. The findings will provide a basis for applying non-invasive brain stimulation (NIBS) in IIDDs treatment and offer new ideas for future personalized medicine approaches.

Who can participate

Age range

18 Years – 60 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age: 18-60 years old. * Diagnosis: Patients with neuromyelitis optica spectrum disease, multiple sclerosis and other inflammatory demyelinating diseases of the central nervous system that meet the diagnostic criteria. * Medications have been stable for at least three months. Exclusion Criteria: * Recurrence has been recorded in the past 3 months. * Have a pacemaker or other metal implant in the body. * Impaired skin integrity at the site of electrode placement. * Previous organic brain disease such as epilepsy, hydrocephalus, central nervous system tumors, brain injury, or intracranial infection. * Combined with severe or unstable organic diseases, such as heart, liver and kidney and other organ dysfunction. * Pregnant or lactating women, those who are planning to become pregnant in the near future. * Patient compliance is poor. * In the opinion of the investigator, there is a situation that is not suitable to participate in this study.

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Expanded Disability Status Scale, EDSS score

Timeframe: At the 5-day point of treatment and 1 month following the end of treatment

Symbol Digit Modalities Test (SDMT) scale

Timeframe: At the 5-day point of treatment and 1 month following the end of treatment

Scoring results for tasks 1 and 7 in the Alzheimer disease assessment scale-cog(ADAS-cog)

Timeframe: At the 5-day point of treatment and 1 month following the end of treatment

Trial details

NCT IDNCT07087873

SponsorXuanwu Hospital, Beijing

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2027-10-31

Contact for this trial

huang huijin, Ph.D.

+8618510510804 huanghuijinmail@sina.com

View on ClinicalTrials.gov More Idiopathic Inflammatory Demyelinating Disorders of the Central Nervous System trials

Plain-language summary

Who can participate

Age range

18 Years – 60 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

What they're measuring

Expanded Disability Status Scale, EDSS score

Timeframe: At the 5-day point of treatment and 1 month following the end of treatment

Symbol Digit Modalities Test (SDMT) scale

Timeframe: At the 5-day point of treatment and 1 month following the end of treatment

Scoring results for tasks 1 and 7 in the Alzheimer disease assessment scale-cog(ADAS-cog)

Timeframe: At the 5-day point of treatment and 1 month following the end of treatment